Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infusion-related reactions of ocrelizumab with adjusted premedication
IRCT20090429001859N10Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Infusion-related reactions of ocrelizumab. Started Jul 2023; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20090429001859N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090429001859N10.